Table 3 1-, 2-, 5-, and 10-year incidence of bone metastases by tumor type and stage at diagnosis

 Stage I (N = 54,305)

0.5 (0.4–0.5)

0.7 (0.7–0.8)

1.5 (1.4–1.6)

2.7 (2.4–2.9)

 Stage II (N = 47,080)

1.1 (1.0–1.2)

1.8 (1.7–1.9)

3.6 (3.4–3.8)

5.9 (5.6–6.3)

 Stage III (N = 35,289)

2.2 (2.0–2.3)

3.3 (3.1–3.5)

5.4 (5.1–5.6)

7.5 (7.1–8.0)

 Stage IV (N = 45,527)

18.0 (17.7–18.4)

20.3 (19.9–20.7)

23.7 (23.3–24.1)

27.6 (27.0–28.2)

 Stage I (N = 37,042)

0.3 (0.3–0.4)

0.5 (0.5–0.6)

1.2 (1.1–1.4)

2.4 (2.1–2.7)

 Stage II (N = 27,886)

1.0 (0.9–1.2)

1.8 (1.6–1.9)

3.9 (3.7–4.2)

6.5 (6.0–6.9)

 Stage III (N = 8720)

2.9 (2.6–3.3)

4.9 (4.4–5.3)

10.1 (9.4–10.8)

15.3 (14.1–16.5)

 Stage IV (N = 5985)

36.4 (35.2–37.7)

41.4 (40.2–42.7)

50.6 (49.3–52.0)

61.4 (59.5–63.2)

 Stage I (N = 533)

3.0 (1.8–4.9)

4.4 (2.9–6.5)

7.7 (5.4–10.8)

12.1 (8.3–17.4)

 Stage II (N = 2737)

3.3 (2.6–4.0)

4.1 (3.4–4.9)

7.3 (6.3–8.4)

15.8 (12.0–20.6)

 Stage III (N = 591)

9.0 (6.9–11.6)

11.5 (9.2–14.4)

16.4 (13.4–19.9)

23.4 (18.7–29.0)

 Stage IV (N = 3908)

45.3 (43.8–46.9)

51.4 (49.9–53.0)

61.1 (59.5–62.8)

70.7 (68.4–72.9)

 Stage I (N = 4955)

1.4 (1.1–1.8)

2.3 (1.9–2.7)

3.6 (3.0–4.2)

5.1 (4.1–6.4)

 Stage II (N = 2603)

2.7 (2.2–3.4)

4.2 (3.4–5.0)

5.6 (4.7–6.7)

8.4 (6.9–10.4)

 Stage III (N = 7540)

4.4 (4.0–4.9)

5.8 (5.3–6.4)

6.7 (6.2–7.3)

7.4 (6.7–8.2)

 Stage IV (N = 13,487)

22.9 (22.2–23.6)

24.5 (23.8–25.3)

25.8 (25.1–26.6)

26.2 (25.4–27.0)

 Stage I (N = 2834)

0.2 (0.1–0.5)

0.4 (0.2–0.7)

1.0 (0.7–1.5)

1.6 (1.0–2.6)

 Stage II (N = 7105)

0.2 (0.1–0.3)

0.5 (0.3–0.7)

1.0 (0.7–1.3)

1.6 (1.1–2.2)

 Stage III (N = 9303)

0.4 (0.3–0.5)

0.7 (0.6–0.9)

1.5 (1.2–1.8)

1.9 (1.6–2.3)

 Stage IV (N = 7125)

3.0 (2.7–3.5)

4.1 (3.7–4.6)

5.8 (5.2–6.4)

6.6 (5.9–7.4)

 Stage I (N = 1424)

0.4 (0.2–0.9)

0.7 (0.3–1.3)

1.5 (0.9–2.5)

2.2 (1.2–3.9)

 Stage II (N = 2998)

0.7 (0.5–1.1)

1.3 (0.9–1.7)

2.2 (1.7–2.9)

2.9 (2.0–4.1)

 Stage III (N = 2584)

1.2 (0.9–1.7)

1.9 (1.4–2.5)

2.7 (2.1–3.4)

2.9 (2.2–3.7)

 Stage IV (N = 5840)

5.3 (4.7–5.9)

6.1 (5.5–6.8)

6.8 (6.2–7.5)

7.4 (6.5–8.4)

 Stage I (N = 3922)

0.2 (0.1–0.4)

0.5 (0.3–0.8)

0.9 (0.6–1.3)

1.9 (1.1–3.2)

 Stage II (N = 1008)

0.6 (0.3–1.3)

1.0 (0.5–1.9)

1.8 (1.1–3.0)

2.0 (1.3–3.3)

 Stage III (N = 3012)

0.7 (0.4–1.0)

1.2 (0.9–1.7)

2.1 (1.6–2.8)

3.1 (1.9–5.1)

 Stage IV (N = 2076)

4.0 (3.3–5.0)

4.7 (3.8–5.7)

6.2 (5.2–7.5)

7.5 (5.9–9.6)

 Stage I (N = 1581)

0.2 (0.1–0.6)

0.3 (0.1–0.7)

0.6 (0.3–1.3)

0.9 (0.4–1.7)

 Stage II (N = 822)

0.7 (0.3–1.6)

1.1 (0.6–2.1)

1.9 (1.1–3.3)

1.9 (1.1–3.3)

 Stage III (N = 877)

0.6 (0.2–1.4)

1.2 (0.6–2.1)

1.2 (0.6–2.1)

1.2 (0.6–2.1)

 Stage IV (N = 752)

6.1 (4.6–8.1)

7.4 (5.7–9.5)

9.0 (7.1–11.5)

10.4 (8.0–13.5)

 Stage I (N = 1654)

0.8 (0.5–1.4)

1.1 (0.7–1.8)

2.4 (1.7–3.4)

5.1 (3.4–7.6)

 Stage II (N = 1297)

1.5 (1.0–2.4)

2.4 (1.7–3.4)

3.9 (2.9–5.3)

5.0 (3.5–7.1)

 Stage III (N = 1210)

2.1 (1.5–3.1)

3.3 (2.4–4.5)

5.0 (3.8–6.5)

6.8 (5.1–9.1)

 Stage IV (N = 2668)

15.5 (14.2–16.9)

18.3 (16.9–19.8)

22.3 (20.7–24.1)

26.2 (23.6–29.0)

 Stage I (N = 360)

0.8 (0.3–2.6)

1.7 (0.8–3.7)

2.1 (1.0–4.4)

5.2 (1.6–16.3)

 Stage II (N = 624)

0.8 (0.3–1.9)

1.3 (0.7–2.6)

3.2 (2.0–5.3)

4.8 (2.9–7.8)

 Stage III (N = 1452)

0.8 (0.4–1.4)

1.5 (1.0–2.3)

1.9 (1.3–2.8)

3.5 (2.1–5.7)

 Stage IV (N = 3686)

2.7 (2.2–3.3)

3.8 (3.2–4.5)

4.6 (4.0–5.4)

5.3 (4.3–6.4)